Empagliflozin significantly reduced estimated extracellular volume by 0.123 L compared to placebo in non-diabetic patients at risk of heart failure.
Does empagliflozin reduce estimated extracellular volume and ventricular epicardial adipose tissue mass in non-diabetic patients with overweight or obesity and risk of heart failure?
In non-diabetic patients with overweight or obesity at risk of heart failure, empagliflozin reduces estimated extracellular volume but does not affect ventricular epicardial adipose tissue mass.
Absolute Event Rate: 0% vs 0%
Abstract Aims Obesity increases the risk of heart failure (HF), partly due to hypervolaemia and excess epicardial adipose tissue (EAT). We aimed to investigate the effect of the sodium glucose co-transporter 2 inhibitor empagliflozin on estimated extracellular volume (eECV) and ventricular EAT mass in non-diabetic patients with overweight or obesity and risk of HF to evaluate the drug’s potential for HF prevention. Methods In this randomised, double-blind, placebo-controlled trial, we recruited non-diabetic patients with body mass index (BMI) 28kg/m2 and risk of HF. Patients were randomised 1:1 to 180-days empagliflozin 10 mg or placebo. The primary endpoints were the baseline-adjusted mean differences in change of eECV and ventricular EAT mass in the intention-to-treat population with Bonferroni-adjustment for multiplicity. Results From September 2021 to July 2024, we randomised 191 patients (empagliflozin: 94, placebo: 97) with median age 68 years and median BMI 31·9 kg/m2. Analyses of eECV and EAT included 191 and 165 patients, respectively. Compared to placebo, empagliflozin significantly reduced eECV empagliflozin, mean change (SD): -0·154 L (0·257); placebo, mean change: -0·029 L (0·261); estimated treatment difference (ETD): -0·123 L, 97.5% CI: -0·211 to -0·035, padj=0·004 but did not affect EAT mass empagliflozin, mean change: -2·3 g (13·4); placebo, mean change: -3·7 g (15·8); ETD: 1·5 g, 97·5% CI: -3·8 to 6·7, padj=1.00. Conclusion In high-risk patients with overweight or obesity, treatment with empagliflozin resulted in a potentially favourable reduction in eECV compared to placebo. Meanwhile, the drug did not affect EAT mass.
Andersen et al. (Wed,) reported a other. Empagliflozin significantly reduced estimated extracellular volume by 0.123 L compared to placebo in non-diabetic patients at risk of heart failure.